The initiation of this study is to assess the added value that Nanoform’s proprietary technology could deliver across the pharmaceutical value chain.
Commenting on the agreement, Edward Hæggström, CEO of Nanoform said:
“We have always believed that our technology has significant value to offer the Pharma industry, particularly in reducing clinical attrition rates by nanonizationTM to increase dissolution rates of poorly soluble APIs and overcome significant bioavailability challenges, as evidenced by the work conducted between us and our pharmaceutical partners.
Producing tailored nanoparticles
This is the first step of hopefully a long and successful relationship between our two companies and we look forward to working closely with AZ to support their early development needs and validating the value of our technology for their products.”
Read also: Nanoform shrinks drug particles